Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.

@article{Chen2002EffectO2,
  title={Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain.},
  author={Shaorui Chen and Krystyna M. Wozniak and Barbara S. Slusher and Hui-Lin Pan},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2002},
  volume={300 2},
  pages={
          662-7
        }
}
  • Shaorui ChenK. Wozniak H. Pan
  • Published 1 February 2002
  • Biology, Medicine
  • The Journal of pharmacology and experimental therapeutics
Increased glutamate availability in the spinal cord and primary afferent nerves plays an important role in acute and chronic pain. Afferent ectopic discharges from the site of nerve injury constitute a source of abnormal sensory input to the spinal dorsal horn. The ectopic afferent activity is largely responsible for the development of hypersensitivity of dorsal horn neurons and neuropathic pain. Inhibition of glutamate carboxypeptidase II (GCP II) reduces glutamate release generated from N… 

Figures from this paper

Distinct Roles of Group III Metabotropic Glutamate Receptors in Control of Nociception and Dorsal Horn Neurons in Normal and Nerve-Injured Rats

Assessment of the effect of the group III mGluR specific agonist l(+)-2-amino-4-phosphonobutyric acid (l-AP4) on nociception and dorsal horn projection neurons in normal rats and a rat model of neuropathic pain suggests that group IIImGluRs play distinct roles in regulation of nocICEption and Lurid pain states.

Local administration of N‐acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats

Understanding of the role of this peptide in sensory neurons is extended and the potential for treatment of inflammatory pain via local application of NAAG peptidase inhibitors at doses that may have little or no central nervous system effects is revealed.

Pharmacokinetics and Pharmacodynamics of the Glutamate Carboxypeptidase II Inhibitor 2-MPPA Show Prolonged Alleviation of Neuropathic Pain through an Indirect Mechanism

The delayed onset, dependence on threshold plasma concentration, and sustained effects after exposure support the hypothesis that an indirect, long-lived mechanism of action exists, and daily clinical dosing of a GCP II inhibitor seems justified.

The Orally Active Glutamate Carboxypeptidase II Inhibitor E2072 Exhibits Sustained Nerve Exposure and Attenuates Peripheral Neuropathy

It is reported that E2072 attenuates hyperalgesia and nerve conduction velocity deficits in preclinical rodent models of neuropathic pain and oxaliplatin-induced neuropathy, and shows no interference with the antineoplastic efficacy of oxali Platin in mice bearing leukemia.

Sciatic Nerve Intrafascicular Lidocaine Injection-induced Peripheral Neuropathic Pain: Alleviation by Systemic Minocycline Administration

Systemic minocycline administration alleviates intrafascicular lidocaine injection-induced peripheral nerve damage and was better than postinjury minocyCline administration in alleviating mechanical behaviors, mitigating macrophage recruitment into the sciatic nerve, and suppressing activated microglial cells in the spinal cord.

Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury

Findings support the hypothesis that GCP II inhibitors may represent a novel treatment for peripheral neuropathies as well as stroke.

References

SHOWING 1-10 OF 40 REFERENCES

Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats.

  • W. XiaoG. Bennett
  • Biology
    The Journal of pharmacology and experimental therapeutics
  • 1995
The results suggest that N-type Ca++ channel blockers may be useful in the treatment of the abnormal pains that occur after nerve injury, including hyperalgesia and allodynia.

Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats.

Electrophysiological evidence is provided that gabapentin is capable of suppressing the ectopic discharge activity from injured peripheral nerves, which may contribute, at least in part, to the antiallodynic effect of gABapentin on neuropathic pain.

Inflammation-induced changes in peripheral glutamate receptor populations

Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists.

It is concluded that systemic NMDA, but not AMPA, receptor antagonists may have an analgesic effect upon the chronic allodynia-like response, and dextromethorphan, which is clinically tolerated and produced less side effects, may be useful for treating chronic pain associated with central nervous system injury.

Peripheral administration of NMDA, AMPA or KA results in pain behaviors in rats

Activation of NMDA, AMPA or KA receptors at the level of the peripheral nerve terminal can produce nociceptive behavior, and data suggest that topical application of glutamate receptor antagonists may be useful in treating pain disorders.

Peripheral NMDA and non‐NMDA glutamate receptors contribute to nociceptive behaviors in the rat formalin test

It is hypothesized that peripheral glutamate receptors on cutaneous axons can be manipulated to reduce certain aspects of pain of peripheral origin and this route of administration offers the advantage of avoiding the side effects of systemic administration.